{"id":344702,"date":"2025-08-24T13:49:09","date_gmt":"2025-08-24T13:49:09","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-catalyst-pharmaceuticals\/"},"modified":"2025-08-24T13:49:09","modified_gmt":"2025-08-24T13:49:09","slug":"how-to-buy-catalyst-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/","title":{"rendered":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX)"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-344702","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX)","h1_source":{"label":"H1","type":"text","formatted_value":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX)"},"description":"T\u00ecm hi\u1ec3u c\u00e1ch mua c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) v\u1edbi h\u01b0\u1edbng d\u1eabn \u0111\u1ea7u t\u01b0 \u0111\u1ea7y \u0111\u1ee7 c\u1ee7a ch\u00fang t\u00f4i bao g\u1ed3m gi\u00e1 hi\u1ec7n t\u1ea1i, r\u1ee7i ro v\u00e0 ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng cho giai \u0111o\u1ea1n 2025-2030.","description_source":{"label":"Description","type":"textarea","formatted_value":"T\u00ecm hi\u1ec3u c\u00e1ch mua c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) v\u1edbi h\u01b0\u1edbng d\u1eabn \u0111\u1ea7u t\u01b0 \u0111\u1ea7y \u0111\u1ee7 c\u1ee7a ch\u00fang t\u00f4i bao g\u1ed3m gi\u00e1 hi\u1ec7n t\u1ea1i, r\u1ee7i ro v\u00e0 ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng cho giai \u0111o\u1ea1n 2025-2030."},"intro":"B\u1ea1n \u0111ang ngh\u0129 \u0111\u1ebfn vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o m\u1ed9t c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m \u0111ang t\u1ea1o d\u1ea5u \u1ea5n trong \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh hi\u1ebfm g\u1eb7p? Catalyst Pharmaceuticals (CPRX) k\u1ebft h\u1ee3p khoa h\u1ecdc ti\u00ean ti\u1ebfn v\u1edbi hi\u1ec7u su\u1ea5t t\u00e0i ch\u00ednh \u1ea5n t\u01b0\u1ee3ng \u2014 ho\u00e0n h\u1ea3o cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 t\u00ecm ki\u1ebfm t\u0103ng tr\u01b0\u1edfng trong l\u0129nh v\u1ef1c ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe. V\u1edbi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb cho c\u00e1c b\u1ec7nh \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn h\u00e0ng ng\u00e0n ng\u01b0\u1eddi tr\u00ean to\u00e0n th\u1ebf gi\u1edbi, c\u00f4ng ty n\u00e0y \u0111\u1ea1i di\u1ec7n cho c\u1ea3 s\u1ef1 \u0111\u1ed5i m\u1edbi y h\u1ecdc v\u00e0 c\u01a1 h\u1ed9i \u0111\u1ea7u t\u01b0.","intro_source":{"label":"Intro","type":"text","formatted_value":"B\u1ea1n \u0111ang ngh\u0129 \u0111\u1ebfn vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o m\u1ed9t c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m \u0111ang t\u1ea1o d\u1ea5u \u1ea5n trong \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh hi\u1ebfm g\u1eb7p? Catalyst Pharmaceuticals (CPRX) k\u1ebft h\u1ee3p khoa h\u1ecdc ti\u00ean ti\u1ebfn v\u1edbi hi\u1ec7u su\u1ea5t t\u00e0i ch\u00ednh \u1ea5n t\u01b0\u1ee3ng \u2014 ho\u00e0n h\u1ea3o cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 t\u00ecm ki\u1ebfm t\u0103ng tr\u01b0\u1edfng trong l\u0129nh v\u1ef1c ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe. V\u1edbi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb cho c\u00e1c b\u1ec7nh \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn h\u00e0ng ng\u00e0n ng\u01b0\u1eddi tr\u00ean to\u00e0n th\u1ebf gi\u1edbi, c\u00f4ng ty n\u00e0y \u0111\u1ea1i di\u1ec7n cho c\u1ea3 s\u1ef1 \u0111\u1ed5i m\u1edbi y h\u1ecdc v\u00e0 c\u01a1 h\u1ed9i \u0111\u1ea7u t\u01b0."},"body_html":"<h2>\ud83d\udcc8 C\u1ed5 Phi\u1ebfu Catalyst Pharmaceuticals: Gi\u00e1 Hi\u1ec7n T\u1ea1i v\u00e0 C\u00e1c Ng\u00e0y Quan Tr\u1ecdng<\/h2> <p>T\u00ednh \u0111\u1ebfn ng\u00e0y 24 th\u00e1ng 8 n\u0103m 2025, Catalyst Pharmaceuticals, Inc. (CPRX) giao d\u1ecbch \u1edf m\u1ee9c <strong>20,23 USD<\/strong> tr\u00ean NASDAQ. Gi\u00e1 n\u00e0y ph\u1ea3n \u00e1nh hi\u1ec7u su\u1ea5t l\u1ee3i nhu\u1eadn qu\u00fd 2 n\u0103m 2025 m\u1ea1nh m\u1ebd c\u1ee7a c\u00f4ng ty v\u00e0 xu h\u01b0\u1edbng t\u0103ng tr\u01b0\u1edfng li\u00ean t\u1ee5c.<\/p> <p><strong>\u0110\u00e1nh d\u1ea5u l\u1ecbch c\u1ee7a b\u1ea1n: Ng\u00e0y 5 th\u00e1ng 11 n\u0103m 2025 l\u00e0 ng\u00e0y v\u00f4 c\u00f9ng quan tr\u1ecdng.<\/strong> \u0110\u00f3 l\u00e0 khi Catalyst c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o l\u1ee3i nhu\u1eadn qu\u00fd 3. L\u1ecbch s\u1eed cho th\u1ea5y c\u00e1c th\u00f4ng b\u00e1o h\u00e0ng qu\u00fd n\u00e0y th\u01b0\u1eddng l\u00e0m bi\u1ebfn \u0111\u1ed9ng c\u1ed5 phi\u1ebfu \u0111\u00e1ng k\u1ec3.<\/p> <h3>C\u00e1ch B\u00e1o C\u00e1o L\u1ee3i Nhu\u1eadn \u1ea2nh H\u01b0\u1edfng \u0110\u1ebfn C\u1ed5 Phi\u1ebfu CPRX<\/h3> <p>Xem x\u00e9t l\u1ecbch s\u1eed g\u1ea7n \u0111\u00e2y cho th\u1ea5y m\u1ed9t m\u00f4 h\u00ecnh r\u00f5 r\u00e0ng v\u1ec1 bi\u1ebfn \u0111\u1ed9ng do l\u1ee3i nhu\u1eadn th\u00fac \u0111\u1ea9y:<\/p> <table> <thead> <tr><th>Ng\u00e0y<\/th><th>S\u1ef1 ki\u1ec7n<\/th><th>Gi\u00e1 Tr\u01b0\u1edbc Tin<\/th><th>Thay \u0110\u1ed5i Sau Tin<\/th><\/tr> <\/thead> <tbody> <tr><td>6 Th\u00e1ng 8, 2025<\/td><td>L\u1ee3i Nhu\u1eadn Qu\u00fd 2<\/td><td>19,68 USD<\/td><td><strong>+2,8%<\/strong> (v\u01b0\u1ee3t d\u1ef1 b\u00e1o)<\/td><\/tr> <tr><td>7 Th\u00e1ng 5, 2025<\/td><td>L\u1ee3i Nhu\u1eadn Qu\u00fd 1<\/td><td>21,50 USD<\/td><td><strong>-4,2%<\/strong> (k\u1ebft qu\u1ea3 h\u1ed7n h\u1ee3p)<\/td><\/tr> <tr><td>26 Th\u00e1ng 2, 2025<\/td><td>K\u1ebft Qu\u1ea3 H\u00e0ng N\u0103m<\/td><td>22,10 USD<\/td><td><strong>+3,1%<\/strong> (h\u01b0\u1edbng d\u1eabn m\u1ea1nh m\u1ebd)<\/td><\/tr> <tr><td>6 Th\u00e1ng 11, 2024<\/td><td>L\u1ee3i Nhu\u1eadn Qu\u00fd 3<\/td><td>20,80 USD<\/td><td><strong>+5,8%<\/strong> (doanh thu b\u1ea5t ng\u1edd)<\/td><\/tr> <tr><td>7 Th\u00e1ng 8, 2024<\/td><td>L\u1ee3i Nhu\u1eadn Qu\u00fd 2<\/td><td>19,20 USD<\/td><td><strong>+9,4%<\/strong> (qu\u00fd k\u1ef7 l\u1ee5c)<\/td><\/tr> <tr><td>9 Th\u00e1ng 5, 2024<\/td><td>Ra M\u1eaft S\u1ea3n Ph\u1ea9m<\/td><td>18,50 USD<\/td><td><strong>+7,0%<\/strong> (m\u1edf r\u1ed9ng th\u1ecb tr\u01b0\u1eddng)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Nh\u1eadn \u0110\u1ecbnh Xu H\u01b0\u1edbng:<\/strong> C\u00e1c b\u1ea5t ng\u1edd l\u1ee3i nhu\u1eadn t\u00edch c\u1ef1c th\u01b0\u1eddng \u0111\u1ea9y CPRX t\u0103ng 5-9%, trong khi c\u00e1c k\u1ebft qu\u1ea3 kh\u00f4ng \u0111\u1ea1t g\u00e2y gi\u1ea3m 3-5%. M\u1ee9c t\u0103ng 9,4% v\u00e0o th\u00e1ng 8 n\u0103m 2024 cho th\u1ea5y tin t\u1ed1t c\u00f3 th\u1ec3 l\u00e0m bi\u1ebfn \u0111\u1ed9ng c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc n\u00e0y m\u1ea1nh m\u1ebd nh\u01b0 th\u1ebf n\u00e0o.<\/p> [cta_green text=\"B\u1eaft \u0111\u1ea7u giao d\u1ecbch\"]<h2>\ud83d\udcca H\u00e0nh Tr\u00ecnh Gi\u00e1 6 Th\u00e1ng (Th\u00e1ng 3 - Th\u00e1ng 8 N\u0103m 2025)<\/h2> <p>C\u1ed5 phi\u1ebfu CPRX \u0111\u00e3 tr\u1ea3i qua bi\u1ebfn \u0111\u1ed9ng \u0111\u00e1ng k\u1ec3 trong giai \u0111o\u1ea1n n\u00e0y, hi\u1ec7n \u0111ang th\u1ec3 hi\u1ec7n <strong>s\u1ef1 t\u0103ng nh\u1eb9 t\u1eeb \u0111\u1ea7u n\u0103m<\/strong> m\u1eb7c d\u00f9 c\u00f3 bi\u1ebfn \u0111\u1ed9ng:<\/p> <p><strong>Th\u00e1ng 3 n\u0103m 2025:<\/strong> 22,50 USD (l\u1ea1c quan sau b\u00e1o c\u00e1o l\u1ee3i nhu\u1eadn)<br\/> <strong>Th\u00e1ng 4 n\u0103m 2025:<\/strong> 21,80 USD (s\u1ef1 \u0111i\u1ec1u ch\u1ec9nh chung c\u1ee7a ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc)<br\/> <strong>Th\u00e1ng 5 n\u0103m 2025:<\/strong> 20,10 USD (th\u1ea5t v\u1ecdng l\u1ee3i nhu\u1eadn qu\u00fd 1)<br\/> <strong>Th\u00e1ng 6 n\u0103m 2025:<\/strong> 26,31 USD (<strong>\u0111\u1ec9nh cao m\u1ecdi th\u1eddi \u0111\u1ea1i<\/strong> \u0111\u1ea1t ng\u00e0y 10 th\u00e1ng 6)<br\/> <strong>Th\u00e1ng 7 n\u0103m 2025:<\/strong> 23,40 USD (ch\u1ed1t l\u1eddi t\u1eeb \u0111\u1ec9nh cao)<br\/> <strong>Th\u00e1ng 8 n\u0103m 2025:<\/strong> 20,23 USD (\u0111i\u1ec1u ch\u1ec9nh hi\u1ec7n t\u1ea1i)<\/p> <p>C\u1ed5 phi\u1ebfu \u0111\u00e3 \u0111\u1ea1t <strong>\u0111\u1ec9nh 26,31 USD v\u00e0o ng\u00e0y 10 th\u00e1ng 6 n\u0103m 2025<\/strong> <a href=\"https:\/\/stockscan.io\/stocks\/CPRX\/forecast\">(StockScan)<\/a>, th\u1ec3 hi\u1ec7n m\u1ed9t \u0111\u1ee3t t\u0103ng m\u1ea1nh t\u1eeb m\u1ee9c th\u1ea5p tr\u01b0\u1edbc \u0111\u00f3. Tuy nhi\u00ean, k\u1ec3 t\u1eeb \u0111\u00f3 \u0111\u00e3 gi\u1ea3m kho\u1ea3ng <strong>23% t\u1eeb \u0111\u1ec9nh<\/strong>, t\u1ea1o ra c\u01a1 h\u1ed9i mua v\u00e0o theo nh\u1eadn \u0111\u1ecbnh c\u1ee7a m\u1ed9t s\u1ed1 nh\u00e0 ph\u00e2n t\u00edch.<\/p> <h3>T\u1ea1i Sao L\u1ea1i C\u00f3 Bi\u1ebfn \u0110\u1ed9ng?<\/h3> <ul> <li><strong>Ph\u00e1t tri\u1ec3n quy \u0111\u1ecbnh FDA<\/strong> \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn ph\u00ea duy\u1ec7t thu\u1ed1c cho b\u1ec7nh hi\u1ebfm<\/li> <li><strong>B\u1ea5t ng\u1edd l\u1ee3i nhu\u1eadn h\u00e0ng qu\u00fd<\/strong> - c\u00f4ng ty \u0111\u00e3 v\u01b0\u1ee3t d\u1ef1 b\u00e1o trong 3 tr\u00ean 4 qu\u00fd g\u1ea7n nh\u1ea5t<\/li> <li><strong>T\u00e2m l\u00fd ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc r\u1ed9ng h\u01a1n<\/strong> - r\u1ea5t nh\u1ea1y c\u1ea3m v\u1edbi l\u00e3i su\u1ea5t v\u00e0 tin t\u1ee9c quy \u0111\u1ecbnh<\/li> <li><strong>C\u1eadp nh\u1eadt th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng<\/strong> cho c\u00e1c s\u1ea3n ph\u1ea9m trong pipeline<\/li> <\/ul> <h2>\ud83d\udd2e D\u1ef1 B\u00e1o Gi\u00e1: Tri\u1ec3n V\u1ecdng 2025-2030<\/h2> <p>D\u1ef1a tr\u00ean d\u1ef1 b\u00e1o c\u1ee7a c\u00e1c nh\u00e0 ph\u00e2n t\u00edch hi\u1ec7n t\u1ea1i v\u00e0 c\u00e1c y\u1ebfu t\u1ed1 c\u01a1 b\u1ea3n c\u1ee7a c\u00f4ng ty:<\/p> <p><strong>Cu\u1ed1i n\u0103m 2025:<\/strong> 25-28 USD (<strong>MUA<\/strong>)<br\/> K\u1ebft qu\u1ea3 qu\u00fd 2 m\u1ea1nh m\u1ebd <a href=\"https:\/\/www.nasdaq.com\/articles\/catalyst-pharmaceuticals-q2-earnings-beat-firdapse-revenues-rise-y-y\">(Nasdaq)<\/a> v\u1edbi t\u0103ng tr\u01b0\u1edfng doanh thu 19,4% h\u1ed7 tr\u1ee3 gi\u00e1 c\u1ed5 phi\u1ebfu ti\u1ebfp t\u1ee5c t\u0103ng \u0111\u1ebfn cu\u1ed1i n\u0103m.<\/p> <p><strong>D\u1ef1 b\u00e1o 2026:<\/strong> 29-34 USD<br\/> C\u00e1c nh\u00e0 ph\u00e2n t\u00edch d\u1ef1 \u0111o\u00e1n <a href=\"https:\/\/aipickup.com\/stock-prediction\/cprx-stock-forecast\">ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng 37,52%<\/a> t\u1eeb m\u1ee9c hi\u1ec7n t\u1ea1i khi doanh s\u1ed1 Agamree t\u0103ng t\u1ed1c.<\/p> <p><strong>D\u1ef1 b\u00e1o 2028:<\/strong> 36-40 USD<br\/> M\u1edf r\u1ed9ng pipeline v\u00e0 th\u00e2m nh\u1eadp th\u1ecb tr\u01b0\u1eddng qu\u1ed1c t\u1ebf c\u00f3 th\u1ec3 t\u1ea1o ra gi\u00e1 tr\u1ecb \u0111\u00e1ng k\u1ec3.<\/p> <p><strong>Tri\u1ec3n v\u1ecdng 2030:<\/strong> 22-25 USD<br\/> D\u1ef1 b\u00e1o d\u00e0i h\u1ea1n cho th\u1ea5y s\u1ef1 \u0111i\u1ec1u ch\u1ec9nh khi c\u00e1c b\u1eb1ng s\u00e1ng ch\u1ebf b\u1eaft \u0111\u1ea7u h\u1ebft h\u1ea1n.<\/p> <p><strong>K\u1ebft lu\u1eadn: MUA M\u1ea0NH cho 2025-2026<\/strong> - Vi\u1ec7c \u0111i\u1ec1u ch\u1ec9nh t\u1eeb \u0111\u1ec9nh th\u00e1ng 6 hi\u1ec7n t\u1ea1i t\u1ea1o \u0111i\u1ec3m v\u00e0o h\u1ea5p d\u1eabn cho nh\u00e0 \u0111\u1ea7u t\u01b0 h\u01b0\u1edbng t\u1edbi t\u0103ng tr\u01b0\u1edfng.<\/p> <h2>\u26a0\ufe0f R\u1ee7i Ro Ch\u00ednh v\u00e0 T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c<\/h2> <h3>R\u1ee7i Ro C\u1ea7n Xem X\u00e9t<\/h3> <ul> <li><strong>R\u1ee7i ro quy \u0111\u1ecbnh FDA:<\/strong> M\u1ed1i \u0111e d\u1ecda l\u1edbn nh\u1ea5t - b\u1ea5t k\u1ef3 quy\u1ebft \u0111\u1ecbnh ti\u00eau c\u1ef1c n\u00e0o c\u00f3 th\u1ec3 \"khi\u1ebfn c\u1ed5 phi\u1ebfu s\u1ee5p \u0111\u1ed5 qua \u0111\u00eam\" <a href=\"https:\/\/www.youtube.com\/watch?v=X_tInhuBbI8\">(Ph\u00e2n t\u00edch \u0111\u1ea7u t\u01b0)<\/a>. Ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u0111\u1ed1i m\u1eb7t v\u1edbi \"s\u1ef1 gi\u00e1m s\u00e1t an to\u00e0n t\u0103ng cao\" trong n\u0103m 2025.<\/li> <li><strong>T\u1eadp trung pipeline:<\/strong> Ph\u1ee5 thu\u1ed9c l\u1edbn v\u00e0o Firdapse (94% doanh thu) t\u1ea1o ra \u0111i\u1ec3m y\u1ebfu n\u1ebfu c\u00f3 c\u1ea1nh tranh ho\u1eb7c \u00e1p l\u1ef1c gi\u00e1 t\u0103ng.<\/li> <li><strong>Bi\u1ebfn \u0111\u1ed9ng th\u1ecb tr\u01b0\u1eddng:<\/strong> Beta 0,78 ngh\u0129a l\u00e0 bi\u1ebfn \u0111\u1ed9ng \u00edt h\u01a1n m\u1ed9t s\u1ed1 c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc kh\u00e1c, nh\u01b0ng v\u1eabn ch\u1ecbu \u1ea3nh h\u01b0\u1edfng t\u1eeb t\u00e2m l\u00fd ng\u00e0nh.<\/li> <li><strong>H\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf:<\/strong> R\u1ee7i ro d\u00e0i h\u1ea1n khi c\u00e1c b\u1ea3o h\u1ed9 thu\u1ed1c ch\u00ednh b\u1eaft \u0111\u1ea7u h\u1ebft h\u1ea1n v\u00e0o cu\u1ed1i th\u1eadp k\u1ef7.<\/li> <\/ul> <h3>T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c Cho N\u0103m 2025<\/h3> <ul> <li><strong>Hi\u1ec7u su\u1ea5t t\u00e0i ch\u00ednh k\u1ef7 l\u1ee5c:<\/strong> Qu\u00fd 2 n\u0103m 2025 \u0111\u1ea1t <a href=\"https:\/\/www.stocktitan.net\/news\/CPRX\/catalyst-pharmaceuticals-reports-record-second-quarter-and-first-2chcg39j187j.html\">146,6 tri\u1ec7u USD doanh thu (+19,4% so v\u1edbi c\u00f9ng k\u1ef3)<\/a> v\u00e0 EPS v\u01b0\u1ee3t d\u1ef1 b\u00e1o 0,68 USD so v\u1edbi 0,58 USD.<\/li> <li><strong>\u0110\u01b0\u1ee3c \u0111\u01b0a v\u00e0o h\u01b0\u1edbng d\u1eabn:<\/strong> X\u00e9t nghi\u1ec7m kh\u00e1ng th\u1ec3 LEMS \u0111\u01b0\u1ee3c th\u00eam v\u00e0o H\u01b0\u1edbng D\u1eabn Th\u1ef1c H\u00e0nh L\u00e2m S\u00e0ng NCCN cho Ung Th\u01b0 Ph\u1ed5i T\u1ebf B\u00e0o Nh\u1ecf - s\u1ef1 x\u00e1c nh\u1eadn quan tr\u1ecdng c\u00f3 th\u1ec3 th\u00fac \u0111\u1ea9y t\u0103ng tr\u01b0\u1edfng \u0111\u01a1n thu\u1ed1c.<\/li> <li><strong>B\u1ea3ng c\u00e2n \u0111\u1ed1i m\u1ea1nh:<\/strong> 652,8 tri\u1ec7u USD ti\u1ec1n m\u1eb7t kh\u00f4ng c\u00f3 n\u1ee3, cung c\u1ea5p s\u1ef1 linh ho\u1ea1t t\u00e0i ch\u00ednh cho mua b\u00e1n ho\u1eb7c \u0111\u1ea7u t\u01b0 R&D.<\/li> <li><strong>H\u1ed7 tr\u1ee3 t\u1eeb nh\u00e0 ph\u00e2n t\u00edch:<\/strong> M\u1ee5c ti\u00eau gi\u00e1 trung b\u00ecnh 34,00 USD th\u1ec3 hi\u1ec7n <a href=\"https:\/\/www.zacks.com\/stock\/research\/CPRX\/price-target-stock-forecast\">ti\u1ec1m n\u0103ng t\u0103ng 62%<\/a> theo c\u00e1c nh\u00e0 ph\u00e2n t\u00edch Ph\u1ed1 Wall.<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Nh\u00e0 Giao D\u1ecbch M\u1edbi N\u00ean L\u00e0m G\u00ec H\u00f4m Nay?<\/h2> <ol> <li><strong>\u0110\u1ea7u t\u01b0 trung b\u00ecnh chi ph\u00ed \u0111\u00f4 la:<\/strong> Do bi\u1ebfn \u0111\u1ed9ng, h\u00e3y \u0111\u1ea7u t\u01b0 s\u1ed1 ti\u1ec1n c\u1ed1 \u0111\u1ecbnh h\u00e0ng tu\u1ea7n thay v\u00ec c\u1ed1 g\u1eafng ch\u1ecdn th\u1eddi \u0111i\u1ec3m mua ho\u00e0n h\u1ea3o<\/li> <li><strong>\u0110\u1eb7t c\u1ea3nh b\u00e1o l\u1ee3i nhu\u1eadn:<\/strong> \u0110\u00e1nh d\u1ea5u ng\u00e0y 5 th\u00e1ng 11 v\u00e0 chu\u1ea9n b\u1ecb cho bi\u1ebfn \u0111\u1ed9ng sau b\u00e1o c\u00e1o l\u1ee3i nhu\u1eadn<\/li> <li><strong>Qu\u1ea3n l\u00fd r\u1ee7i ro:<\/strong> Ph\u00e2n b\u1ed5 kh\u00f4ng qu\u00e1 5-10% danh m\u1ee5c cho c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc ri\u00eang l\u1ebb<\/li> <li><strong>Quan \u0111i\u1ec3m d\u00e0i h\u1ea1n:<\/strong> \u0110\u1ea7u t\u01b0 c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u0111\u00f2i h\u1ecfi ki\u00ean nh\u1eabn qua c\u00e1c chu k\u1ef3 quy \u0111\u1ecbnh<\/li> <\/ol> <p>G\u00f3c nh\u00ecn h\u00e0i h\u01b0\u1edbc: \"Giao d\u1ecbch CPRX gi\u1ed1ng nh\u01b0 xem phim y khoa - \u0111\u1ea7y h\u1ed3i h\u1ed9p, th\u1ec9nh tho\u1ea3ng c\u00f3 \u0111\u1ed9t ph\u00e1, v\u00e0 b\u1ea1n kh\u00f4ng bao gi\u1edd bi\u1ebft khi n\u00e0o FDA s\u1ebd \u0111\u00f3ng vai ph\u1ea3n di\u1ec7n!\"<\/p> <h2>\u2705 C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) - T\u1eebng B\u01b0\u1edbc<\/h2> <table> <thead> <tr><th>B\u01b0\u1edbc<\/th><th>H\u00e0nh \u0110\u1ed9ng<\/th><th>T\u1ea1i Sao Quan Tr\u1ecdng<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Ch\u1ecdn n\u1ec1n t\u1ea3ng giao d\u1ecbch<\/td><td>\u0110\u1ea3m b\u1ea3o n\u1ec1n t\u1ea3ng c\u00f3 truy c\u1eadp NASDAQ v\u00e0 ph\u00ed hoa h\u1ed3ng h\u1ee3p l\u00fd<\/td><\/tr> <tr><td>2<\/td><td>Ho\u00e0n t\u1ea5t n\u1ea1p ti\u1ec1n v\u00e0o t\u00e0i kho\u1ea3n<\/td><td>B\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n b\u1ea1n c\u1ea3m th\u1ea5y tho\u1ea3i m\u00e1i khi r\u1ee7i ro trong ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc bi\u1ebfn \u0111\u1ed9ng<\/td><\/tr> <tr><td>3<\/td><td>T\u00ecm ki\u1ebfm \"CPRX\"<\/td><td>S\u1eed d\u1ee5ng m\u00e3 ch\u1ee9ng kho\u00e1n, kh\u00f4ng ch\u1ec9 t\u00ean c\u00f4ng ty<\/td><\/tr> <tr><td>4<\/td><td>Ch\u1ecdn lo\u1ea1i l\u1ec7nh<\/td><td>L\u1ec7nh gi\u1edbi h\u1ea1n gi\u00fap tr\u00e1nh tr\u1ea3 gi\u00e1 qu\u00e1 cao trong giai \u0111o\u1ea1n bi\u1ebfn \u0111\u1ed9ng<\/td><\/tr> <tr><td>5<\/td><td>Xem l\u1ea1i v\u00e0 x\u00e1c nh\u1eadn<\/td><td>Ki\u1ec3m tra k\u1ef9 c\u00e1c chi ti\u1ebft l\u1ec7nh tr\u01b0\u1edbc khi ho\u00e0n t\u1ea5t mua<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 T\u1ea1i Sao Pocket Option Ph\u00f9 H\u1ee3p V\u1edbi Nh\u00e0 \u0110\u1ea7u T\u01b0 M\u1edbi<\/h2> <p>\u0110\u1ed1i v\u1edbi nh\u1eefng ng\u01b0\u1eddi m\u1edbi b\u1eaft \u0111\u1ea7u h\u00e0nh tr\u00ecnh \u0111\u1ea7u t\u01b0, Pocket Option cung c\u1ea5p nhi\u1ec1u l\u1ee3i th\u1ebf khi giao d\u1ecbch c\u1ed5 phi\u1ebfu nh\u01b0 CPRX:<\/p> <ul> <li><strong>S\u1ed1 ti\u1ec1n n\u1ea1p t\u1ed1i thi\u1ec3u ch\u1ec9 5 USD<\/strong> - ho\u00e0n h\u1ea3o \u0111\u1ec3 th\u1eed nghi\u1ec7m chi\u1ebfn l\u01b0\u1ee3c v\u1edbi r\u1ee7i ro t\u1ed1i thi\u1ec3u<\/li> <li><strong>X\u00e1c minh nhanh ch\u00f3ng<\/strong> - b\u1eaft \u0111\u1ea7u giao d\u1ecbch nhanh v\u1edbi vi\u1ec7c t\u1ea3i l\u00ean t\u00e0i li\u1ec7u \u0111\u01a1n gi\u1ea3n<\/li> <li><strong>Nhi\u1ec1u l\u1ef1a ch\u1ecdn r\u00fat ti\u1ec1n<\/strong> - linh ho\u1ea1t trong vi\u1ec7c ti\u1ebfp c\u1eadn l\u1ee3i nhu\u1eadn c\u1ee7a b\u1ea1n<\/li> <li><strong>N\u1ec1n t\u1ea3ng th\u00e2n thi\u1ec7n v\u1edbi ng\u01b0\u1eddi d\u00f9ng<\/strong> - giao di\u1ec7n tr\u1ef1c quan l\u00fd t\u01b0\u1edfng cho vi\u1ec7c h\u1ecdc \u0111\u1ea7u t\u01b0 c\u00f4ng ngh\u1ec7 sinh h\u1ecdc<\/li> <\/ul> <h2>\ud83c\udf0d Catalyst Pharmaceuticals N\u0103m 2025: Chuy\u00ean Gia B\u1ec7nh Hi\u1ebfm<\/h2> <p>Catalyst Pharmaceuticals chi\u1ebfm l\u0129nh th\u1ecb tr\u01b0\u1eddng b\u1ec7nh th\u1ea7n kinh hi\u1ebfm v\u1edbi s\u1ea3n ph\u1ea9m ch\u1ee7 l\u1ef1c Firdapse, \u0111i\u1ec1u tr\u1ecb H\u1ed9i Ch\u1ee9ng Lambert-Eaton Myasthenic (LEMS). C\u00f4ng ty \u0111\u00e3 chuy\u1ec3n m\u00ecnh t\u1eeb l\u0129nh v\u1ef1c \u0111i\u1ec1u tr\u1ecb nghi\u1ec7n sang tr\u1edf th\u00e0nh <a href=\"https:\/\/catalystpharma.com\/about-catalyst\/\">chuy\u00ean gia b\u1ec7nh hi\u1ebfm t\u1eadp trung<\/a> v\u1edbi ph\u01b0\u01a1ng ph\u00e1p ti\u1ebfp c\u1eadn c\u00f3 s\u1ee9 m\u1ec7nh r\u00f5 r\u00e0ng.<\/p> <p>S\u1ef1 chuy\u1ec3n \u0111\u1ed5i t\u00e0i ch\u00ednh \u1ea5n t\u01b0\u1ee3ng c\u1ee7a c\u00f4ng ty \u0111\u01b0\u1ee3c ch\u1ee9ng minh qua v\u1ecb tr\u00ed <a href=\"https:\/\/dcfmodeling.com\/blogs\/history\/cprx-history-mission-ownership\">th\u1ee9 n\u0103m trong danh s\u00e1ch 50 c\u00f4ng ty Mid-Cap th\u00e0nh c\u00f4ng nh\u1ea5t n\u01b0\u1edbc M\u1ef9 n\u0103m 2025 c\u1ee7a Forbes<\/a> v\u1edbi doanh thu g\u1ea7n 500 tri\u1ec7u USD m\u1ed7i n\u0103m.<\/p> <p><strong>S\u1ef1 th\u1eadt th\u00fa v\u1ecb cho n\u0103m 2025:<\/strong> C\u00e1c ch\u01b0\u01a1ng tr\u00ecnh h\u1ed7 tr\u1ee3 b\u1ec7nh nh\u00e2n c\u1ee7a Catalyst hi\u1ec7n bao g\u1ed3m gi\u00e1m s\u00e1t tu\u00e2n th\u1ee7 \u0111i\u1ec1u tr\u1ecb b\u1eb1ng AI - s\u1eed d\u1ee5ng h\u1ecdc m\u00e1y \u0111\u1ec3 d\u1ef1 \u0111o\u00e1n b\u1ec7nh nh\u00e2n n\u00e0o c\u00f3 th\u1ec3 c\u1ea7n h\u1ed7 tr\u1ee3 th\u00eam d\u1ef1a tr\u00ean m\u1eabu \u0111\u01a1n thu\u1ed1c v\u00e0 d\u1eef li\u1ec7u k\u1ebft qu\u1ea3 l\u00e2m s\u00e0ng.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 C\u1ed5 Phi\u1ebfu Catalyst Pharmaceuticals: Gi\u00e1 Hi\u1ec7n T\u1ea1i v\u00e0 C\u00e1c Ng\u00e0y Quan Tr\u1ecdng<\/h2>\n<p>T\u00ednh \u0111\u1ebfn ng\u00e0y 24 th\u00e1ng 8 n\u0103m 2025, Catalyst Pharmaceuticals, Inc. (CPRX) giao d\u1ecbch \u1edf m\u1ee9c <strong>20,23 USD<\/strong> tr\u00ean NASDAQ. Gi\u00e1 n\u00e0y ph\u1ea3n \u00e1nh hi\u1ec7u su\u1ea5t l\u1ee3i nhu\u1eadn qu\u00fd 2 n\u0103m 2025 m\u1ea1nh m\u1ebd c\u1ee7a c\u00f4ng ty v\u00e0 xu h\u01b0\u1edbng t\u0103ng tr\u01b0\u1edfng li\u00ean t\u1ee5c.<\/p>\n<p><strong>\u0110\u00e1nh d\u1ea5u l\u1ecbch c\u1ee7a b\u1ea1n: Ng\u00e0y 5 th\u00e1ng 11 n\u0103m 2025 l\u00e0 ng\u00e0y v\u00f4 c\u00f9ng quan tr\u1ecdng.<\/strong> \u0110\u00f3 l\u00e0 khi Catalyst c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o l\u1ee3i nhu\u1eadn qu\u00fd 3. L\u1ecbch s\u1eed cho th\u1ea5y c\u00e1c th\u00f4ng b\u00e1o h\u00e0ng qu\u00fd n\u00e0y th\u01b0\u1eddng l\u00e0m bi\u1ebfn \u0111\u1ed9ng c\u1ed5 phi\u1ebfu \u0111\u00e1ng k\u1ec3.<\/p>\n<h3>C\u00e1ch B\u00e1o C\u00e1o L\u1ee3i Nhu\u1eadn \u1ea2nh H\u01b0\u1edfng \u0110\u1ebfn C\u1ed5 Phi\u1ebfu CPRX<\/h3>\n<p>Xem x\u00e9t l\u1ecbch s\u1eed g\u1ea7n \u0111\u00e2y cho th\u1ea5y m\u1ed9t m\u00f4 h\u00ecnh r\u00f5 r\u00e0ng v\u1ec1 bi\u1ebfn \u0111\u1ed9ng do l\u1ee3i nhu\u1eadn th\u00fac \u0111\u1ea9y:<\/p>\n<table>\n<thead>\n<tr>\n<th>Ng\u00e0y<\/th>\n<th>S\u1ef1 ki\u1ec7n<\/th>\n<th>Gi\u00e1 Tr\u01b0\u1edbc Tin<\/th>\n<th>Thay \u0110\u1ed5i Sau Tin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>6 Th\u00e1ng 8, 2025<\/td>\n<td>L\u1ee3i Nhu\u1eadn Qu\u00fd 2<\/td>\n<td>19,68 USD<\/td>\n<td><strong>+2,8%<\/strong> (v\u01b0\u1ee3t d\u1ef1 b\u00e1o)<\/td>\n<\/tr>\n<tr>\n<td>7 Th\u00e1ng 5, 2025<\/td>\n<td>L\u1ee3i Nhu\u1eadn Qu\u00fd 1<\/td>\n<td>21,50 USD<\/td>\n<td><strong>-4,2%<\/strong> (k\u1ebft qu\u1ea3 h\u1ed7n h\u1ee3p)<\/td>\n<\/tr>\n<tr>\n<td>26 Th\u00e1ng 2, 2025<\/td>\n<td>K\u1ebft Qu\u1ea3 H\u00e0ng N\u0103m<\/td>\n<td>22,10 USD<\/td>\n<td><strong>+3,1%<\/strong> (h\u01b0\u1edbng d\u1eabn m\u1ea1nh m\u1ebd)<\/td>\n<\/tr>\n<tr>\n<td>6 Th\u00e1ng 11, 2024<\/td>\n<td>L\u1ee3i Nhu\u1eadn Qu\u00fd 3<\/td>\n<td>20,80 USD<\/td>\n<td><strong>+5,8%<\/strong> (doanh thu b\u1ea5t ng\u1edd)<\/td>\n<\/tr>\n<tr>\n<td>7 Th\u00e1ng 8, 2024<\/td>\n<td>L\u1ee3i Nhu\u1eadn Qu\u00fd 2<\/td>\n<td>19,20 USD<\/td>\n<td><strong>+9,4%<\/strong> (qu\u00fd k\u1ef7 l\u1ee5c)<\/td>\n<\/tr>\n<tr>\n<td>9 Th\u00e1ng 5, 2024<\/td>\n<td>Ra M\u1eaft S\u1ea3n Ph\u1ea9m<\/td>\n<td>18,50 USD<\/td>\n<td><strong>+7,0%<\/strong> (m\u1edf r\u1ed9ng th\u1ecb tr\u01b0\u1eddng)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Nh\u1eadn \u0110\u1ecbnh Xu H\u01b0\u1edbng:<\/strong> C\u00e1c b\u1ea5t ng\u1edd l\u1ee3i nhu\u1eadn t\u00edch c\u1ef1c th\u01b0\u1eddng \u0111\u1ea9y CPRX t\u0103ng 5-9%, trong khi c\u00e1c k\u1ebft qu\u1ea3 kh\u00f4ng \u0111\u1ea1t g\u00e2y gi\u1ea3m 3-5%. M\u1ee9c t\u0103ng 9,4% v\u00e0o th\u00e1ng 8 n\u0103m 2024 cho th\u1ea5y tin t\u1ed1t c\u00f3 th\u1ec3 l\u00e0m bi\u1ebfn \u0111\u1ed9ng c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc n\u00e0y m\u1ea1nh m\u1ebd nh\u01b0 th\u1ebf n\u00e0o.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/vt\/register\/\" class=\"po-cta-green\">B\u1eaft \u0111\u1ea7u giao d\u1ecbch\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca H\u00e0nh Tr\u00ecnh Gi\u00e1 6 Th\u00e1ng (Th\u00e1ng 3 &#8211; Th\u00e1ng 8 N\u0103m 2025)<\/h2>\n<p>C\u1ed5 phi\u1ebfu CPRX \u0111\u00e3 tr\u1ea3i qua bi\u1ebfn \u0111\u1ed9ng \u0111\u00e1ng k\u1ec3 trong giai \u0111o\u1ea1n n\u00e0y, hi\u1ec7n \u0111ang th\u1ec3 hi\u1ec7n <strong>s\u1ef1 t\u0103ng nh\u1eb9 t\u1eeb \u0111\u1ea7u n\u0103m<\/strong> m\u1eb7c d\u00f9 c\u00f3 bi\u1ebfn \u0111\u1ed9ng:<\/p>\n<p><strong>Th\u00e1ng 3 n\u0103m 2025:<\/strong> 22,50 USD (l\u1ea1c quan sau b\u00e1o c\u00e1o l\u1ee3i nhu\u1eadn)<br \/> <strong>Th\u00e1ng 4 n\u0103m 2025:<\/strong> 21,80 USD (s\u1ef1 \u0111i\u1ec1u ch\u1ec9nh chung c\u1ee7a ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc)<br \/> <strong>Th\u00e1ng 5 n\u0103m 2025:<\/strong> 20,10 USD (th\u1ea5t v\u1ecdng l\u1ee3i nhu\u1eadn qu\u00fd 1)<br \/> <strong>Th\u00e1ng 6 n\u0103m 2025:<\/strong> 26,31 USD (<strong>\u0111\u1ec9nh cao m\u1ecdi th\u1eddi \u0111\u1ea1i<\/strong> \u0111\u1ea1t ng\u00e0y 10 th\u00e1ng 6)<br \/> <strong>Th\u00e1ng 7 n\u0103m 2025:<\/strong> 23,40 USD (ch\u1ed1t l\u1eddi t\u1eeb \u0111\u1ec9nh cao)<br \/> <strong>Th\u00e1ng 8 n\u0103m 2025:<\/strong> 20,23 USD (\u0111i\u1ec1u ch\u1ec9nh hi\u1ec7n t\u1ea1i)<\/p>\n<p>C\u1ed5 phi\u1ebfu \u0111\u00e3 \u0111\u1ea1t <strong>\u0111\u1ec9nh 26,31 USD v\u00e0o ng\u00e0y 10 th\u00e1ng 6 n\u0103m 2025<\/strong> <a href=\"https:\/\/stockscan.io\/stocks\/CPRX\/forecast\">(StockScan)<\/a>, th\u1ec3 hi\u1ec7n m\u1ed9t \u0111\u1ee3t t\u0103ng m\u1ea1nh t\u1eeb m\u1ee9c th\u1ea5p tr\u01b0\u1edbc \u0111\u00f3. Tuy nhi\u00ean, k\u1ec3 t\u1eeb \u0111\u00f3 \u0111\u00e3 gi\u1ea3m kho\u1ea3ng <strong>23% t\u1eeb \u0111\u1ec9nh<\/strong>, t\u1ea1o ra c\u01a1 h\u1ed9i mua v\u00e0o theo nh\u1eadn \u0111\u1ecbnh c\u1ee7a m\u1ed9t s\u1ed1 nh\u00e0 ph\u00e2n t\u00edch.<\/p>\n<h3>T\u1ea1i Sao L\u1ea1i C\u00f3 Bi\u1ebfn \u0110\u1ed9ng?<\/h3>\n<ul>\n<li><strong>Ph\u00e1t tri\u1ec3n quy \u0111\u1ecbnh FDA<\/strong> \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn ph\u00ea duy\u1ec7t thu\u1ed1c cho b\u1ec7nh hi\u1ebfm<\/li>\n<li><strong>B\u1ea5t ng\u1edd l\u1ee3i nhu\u1eadn h\u00e0ng qu\u00fd<\/strong> &#8211; c\u00f4ng ty \u0111\u00e3 v\u01b0\u1ee3t d\u1ef1 b\u00e1o trong 3 tr\u00ean 4 qu\u00fd g\u1ea7n nh\u1ea5t<\/li>\n<li><strong>T\u00e2m l\u00fd ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc r\u1ed9ng h\u01a1n<\/strong> &#8211; r\u1ea5t nh\u1ea1y c\u1ea3m v\u1edbi l\u00e3i su\u1ea5t v\u00e0 tin t\u1ee9c quy \u0111\u1ecbnh<\/li>\n<li><strong>C\u1eadp nh\u1eadt th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng<\/strong> cho c\u00e1c s\u1ea3n ph\u1ea9m trong pipeline<\/li>\n<\/ul>\n<h2>\ud83d\udd2e D\u1ef1 B\u00e1o Gi\u00e1: Tri\u1ec3n V\u1ecdng 2025-2030<\/h2>\n<p>D\u1ef1a tr\u00ean d\u1ef1 b\u00e1o c\u1ee7a c\u00e1c nh\u00e0 ph\u00e2n t\u00edch hi\u1ec7n t\u1ea1i v\u00e0 c\u00e1c y\u1ebfu t\u1ed1 c\u01a1 b\u1ea3n c\u1ee7a c\u00f4ng ty:<\/p>\n<p><strong>Cu\u1ed1i n\u0103m 2025:<\/strong> 25-28 USD (<strong>MUA<\/strong>)<br \/> K\u1ebft qu\u1ea3 qu\u00fd 2 m\u1ea1nh m\u1ebd <a href=\"https:\/\/www.nasdaq.com\/articles\/catalyst-pharmaceuticals-q2-earnings-beat-firdapse-revenues-rise-y-y\">(Nasdaq)<\/a> v\u1edbi t\u0103ng tr\u01b0\u1edfng doanh thu 19,4% h\u1ed7 tr\u1ee3 gi\u00e1 c\u1ed5 phi\u1ebfu ti\u1ebfp t\u1ee5c t\u0103ng \u0111\u1ebfn cu\u1ed1i n\u0103m.<\/p>\n<p><strong>D\u1ef1 b\u00e1o 2026:<\/strong> 29-34 USD<br \/> C\u00e1c nh\u00e0 ph\u00e2n t\u00edch d\u1ef1 \u0111o\u00e1n <a href=\"https:\/\/aipickup.com\/stock-prediction\/cprx-stock-forecast\">ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng 37,52%<\/a> t\u1eeb m\u1ee9c hi\u1ec7n t\u1ea1i khi doanh s\u1ed1 Agamree t\u0103ng t\u1ed1c.<\/p>\n<p><strong>D\u1ef1 b\u00e1o 2028:<\/strong> 36-40 USD<br \/> M\u1edf r\u1ed9ng pipeline v\u00e0 th\u00e2m nh\u1eadp th\u1ecb tr\u01b0\u1eddng qu\u1ed1c t\u1ebf c\u00f3 th\u1ec3 t\u1ea1o ra gi\u00e1 tr\u1ecb \u0111\u00e1ng k\u1ec3.<\/p>\n<p><strong>Tri\u1ec3n v\u1ecdng 2030:<\/strong> 22-25 USD<br \/> D\u1ef1 b\u00e1o d\u00e0i h\u1ea1n cho th\u1ea5y s\u1ef1 \u0111i\u1ec1u ch\u1ec9nh khi c\u00e1c b\u1eb1ng s\u00e1ng ch\u1ebf b\u1eaft \u0111\u1ea7u h\u1ebft h\u1ea1n.<\/p>\n<p><strong>K\u1ebft lu\u1eadn: MUA M\u1ea0NH cho 2025-2026<\/strong> &#8211; Vi\u1ec7c \u0111i\u1ec1u ch\u1ec9nh t\u1eeb \u0111\u1ec9nh th\u00e1ng 6 hi\u1ec7n t\u1ea1i t\u1ea1o \u0111i\u1ec3m v\u00e0o h\u1ea5p d\u1eabn cho nh\u00e0 \u0111\u1ea7u t\u01b0 h\u01b0\u1edbng t\u1edbi t\u0103ng tr\u01b0\u1edfng.<\/p>\n<h2>\u26a0\ufe0f R\u1ee7i Ro Ch\u00ednh v\u00e0 T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c<\/h2>\n<h3>R\u1ee7i Ro C\u1ea7n Xem X\u00e9t<\/h3>\n<ul>\n<li><strong>R\u1ee7i ro quy \u0111\u1ecbnh FDA:<\/strong> M\u1ed1i \u0111e d\u1ecda l\u1edbn nh\u1ea5t &#8211; b\u1ea5t k\u1ef3 quy\u1ebft \u0111\u1ecbnh ti\u00eau c\u1ef1c n\u00e0o c\u00f3 th\u1ec3 &#8220;khi\u1ebfn c\u1ed5 phi\u1ebfu s\u1ee5p \u0111\u1ed5 qua \u0111\u00eam&#8221; <a href=\"https:\/\/www.youtube.com\/watch?v=X_tInhuBbI8\">(Ph\u00e2n t\u00edch \u0111\u1ea7u t\u01b0)<\/a>. Ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u0111\u1ed1i m\u1eb7t v\u1edbi &#8220;s\u1ef1 gi\u00e1m s\u00e1t an to\u00e0n t\u0103ng cao&#8221; trong n\u0103m 2025.<\/li>\n<li><strong>T\u1eadp trung pipeline:<\/strong> Ph\u1ee5 thu\u1ed9c l\u1edbn v\u00e0o Firdapse (94% doanh thu) t\u1ea1o ra \u0111i\u1ec3m y\u1ebfu n\u1ebfu c\u00f3 c\u1ea1nh tranh ho\u1eb7c \u00e1p l\u1ef1c gi\u00e1 t\u0103ng.<\/li>\n<li><strong>Bi\u1ebfn \u0111\u1ed9ng th\u1ecb tr\u01b0\u1eddng:<\/strong> Beta 0,78 ngh\u0129a l\u00e0 bi\u1ebfn \u0111\u1ed9ng \u00edt h\u01a1n m\u1ed9t s\u1ed1 c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc kh\u00e1c, nh\u01b0ng v\u1eabn ch\u1ecbu \u1ea3nh h\u01b0\u1edfng t\u1eeb t\u00e2m l\u00fd ng\u00e0nh.<\/li>\n<li><strong>H\u1ebft h\u1ea1n b\u1eb1ng s\u00e1ng ch\u1ebf:<\/strong> R\u1ee7i ro d\u00e0i h\u1ea1n khi c\u00e1c b\u1ea3o h\u1ed9 thu\u1ed1c ch\u00ednh b\u1eaft \u0111\u1ea7u h\u1ebft h\u1ea1n v\u00e0o cu\u1ed1i th\u1eadp k\u1ef7.<\/li>\n<\/ul>\n<h3>T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c Cho N\u0103m 2025<\/h3>\n<ul>\n<li><strong>Hi\u1ec7u su\u1ea5t t\u00e0i ch\u00ednh k\u1ef7 l\u1ee5c:<\/strong> Qu\u00fd 2 n\u0103m 2025 \u0111\u1ea1t <a href=\"https:\/\/www.stocktitan.net\/news\/CPRX\/catalyst-pharmaceuticals-reports-record-second-quarter-and-first-2chcg39j187j.html\">146,6 tri\u1ec7u USD doanh thu (+19,4% so v\u1edbi c\u00f9ng k\u1ef3)<\/a> v\u00e0 EPS v\u01b0\u1ee3t d\u1ef1 b\u00e1o 0,68 USD so v\u1edbi 0,58 USD.<\/li>\n<li><strong>\u0110\u01b0\u1ee3c \u0111\u01b0a v\u00e0o h\u01b0\u1edbng d\u1eabn:<\/strong> X\u00e9t nghi\u1ec7m kh\u00e1ng th\u1ec3 LEMS \u0111\u01b0\u1ee3c th\u00eam v\u00e0o H\u01b0\u1edbng D\u1eabn Th\u1ef1c H\u00e0nh L\u00e2m S\u00e0ng NCCN cho Ung Th\u01b0 Ph\u1ed5i T\u1ebf B\u00e0o Nh\u1ecf &#8211; s\u1ef1 x\u00e1c nh\u1eadn quan tr\u1ecdng c\u00f3 th\u1ec3 th\u00fac \u0111\u1ea9y t\u0103ng tr\u01b0\u1edfng \u0111\u01a1n thu\u1ed1c.<\/li>\n<li><strong>B\u1ea3ng c\u00e2n \u0111\u1ed1i m\u1ea1nh:<\/strong> 652,8 tri\u1ec7u USD ti\u1ec1n m\u1eb7t kh\u00f4ng c\u00f3 n\u1ee3, cung c\u1ea5p s\u1ef1 linh ho\u1ea1t t\u00e0i ch\u00ednh cho mua b\u00e1n ho\u1eb7c \u0111\u1ea7u t\u01b0 R&#038;D.<\/li>\n<li><strong>H\u1ed7 tr\u1ee3 t\u1eeb nh\u00e0 ph\u00e2n t\u00edch:<\/strong> M\u1ee5c ti\u00eau gi\u00e1 trung b\u00ecnh 34,00 USD th\u1ec3 hi\u1ec7n <a href=\"https:\/\/www.zacks.com\/stock\/research\/CPRX\/price-target-stock-forecast\">ti\u1ec1m n\u0103ng t\u0103ng 62%<\/a> theo c\u00e1c nh\u00e0 ph\u00e2n t\u00edch Ph\u1ed1 Wall.<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Nh\u00e0 Giao D\u1ecbch M\u1edbi N\u00ean L\u00e0m G\u00ec H\u00f4m Nay?<\/h2>\n<ol>\n<li><strong>\u0110\u1ea7u t\u01b0 trung b\u00ecnh chi ph\u00ed \u0111\u00f4 la:<\/strong> Do bi\u1ebfn \u0111\u1ed9ng, h\u00e3y \u0111\u1ea7u t\u01b0 s\u1ed1 ti\u1ec1n c\u1ed1 \u0111\u1ecbnh h\u00e0ng tu\u1ea7n thay v\u00ec c\u1ed1 g\u1eafng ch\u1ecdn th\u1eddi \u0111i\u1ec3m mua ho\u00e0n h\u1ea3o<\/li>\n<li><strong>\u0110\u1eb7t c\u1ea3nh b\u00e1o l\u1ee3i nhu\u1eadn:<\/strong> \u0110\u00e1nh d\u1ea5u ng\u00e0y 5 th\u00e1ng 11 v\u00e0 chu\u1ea9n b\u1ecb cho bi\u1ebfn \u0111\u1ed9ng sau b\u00e1o c\u00e1o l\u1ee3i nhu\u1eadn<\/li>\n<li><strong>Qu\u1ea3n l\u00fd r\u1ee7i ro:<\/strong> Ph\u00e2n b\u1ed5 kh\u00f4ng qu\u00e1 5-10% danh m\u1ee5c cho c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc ri\u00eang l\u1ebb<\/li>\n<li><strong>Quan \u0111i\u1ec3m d\u00e0i h\u1ea1n:<\/strong> \u0110\u1ea7u t\u01b0 c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u0111\u00f2i h\u1ecfi ki\u00ean nh\u1eabn qua c\u00e1c chu k\u1ef3 quy \u0111\u1ecbnh<\/li>\n<\/ol>\n<p>G\u00f3c nh\u00ecn h\u00e0i h\u01b0\u1edbc: &#8220;Giao d\u1ecbch CPRX gi\u1ed1ng nh\u01b0 xem phim y khoa &#8211; \u0111\u1ea7y h\u1ed3i h\u1ed9p, th\u1ec9nh tho\u1ea3ng c\u00f3 \u0111\u1ed9t ph\u00e1, v\u00e0 b\u1ea1n kh\u00f4ng bao gi\u1edd bi\u1ebft khi n\u00e0o FDA s\u1ebd \u0111\u00f3ng vai ph\u1ea3n di\u1ec7n!&#8221;<\/p>\n<h2>\u2705 C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) &#8211; T\u1eebng B\u01b0\u1edbc<\/h2>\n<table>\n<thead>\n<tr>\n<th>B\u01b0\u1edbc<\/th>\n<th>H\u00e0nh \u0110\u1ed9ng<\/th>\n<th>T\u1ea1i Sao Quan Tr\u1ecdng<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Ch\u1ecdn n\u1ec1n t\u1ea3ng giao d\u1ecbch<\/td>\n<td>\u0110\u1ea3m b\u1ea3o n\u1ec1n t\u1ea3ng c\u00f3 truy c\u1eadp NASDAQ v\u00e0 ph\u00ed hoa h\u1ed3ng h\u1ee3p l\u00fd<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Ho\u00e0n t\u1ea5t n\u1ea1p ti\u1ec1n v\u00e0o t\u00e0i kho\u1ea3n<\/td>\n<td>B\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n b\u1ea1n c\u1ea3m th\u1ea5y tho\u1ea3i m\u00e1i khi r\u1ee7i ro trong ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc bi\u1ebfn \u0111\u1ed9ng<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>T\u00ecm ki\u1ebfm &#8220;CPRX&#8221;<\/td>\n<td>S\u1eed d\u1ee5ng m\u00e3 ch\u1ee9ng kho\u00e1n, kh\u00f4ng ch\u1ec9 t\u00ean c\u00f4ng ty<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Ch\u1ecdn lo\u1ea1i l\u1ec7nh<\/td>\n<td>L\u1ec7nh gi\u1edbi h\u1ea1n gi\u00fap tr\u00e1nh tr\u1ea3 gi\u00e1 qu\u00e1 cao trong giai \u0111o\u1ea1n bi\u1ebfn \u0111\u1ed9ng<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Xem l\u1ea1i v\u00e0 x\u00e1c nh\u1eadn<\/td>\n<td>Ki\u1ec3m tra k\u1ef9 c\u00e1c chi ti\u1ebft l\u1ec7nh tr\u01b0\u1edbc khi ho\u00e0n t\u1ea5t mua<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 T\u1ea1i Sao Pocket Option Ph\u00f9 H\u1ee3p V\u1edbi Nh\u00e0 \u0110\u1ea7u T\u01b0 M\u1edbi<\/h2>\n<p>\u0110\u1ed1i v\u1edbi nh\u1eefng ng\u01b0\u1eddi m\u1edbi b\u1eaft \u0111\u1ea7u h\u00e0nh tr\u00ecnh \u0111\u1ea7u t\u01b0, Pocket Option cung c\u1ea5p nhi\u1ec1u l\u1ee3i th\u1ebf khi giao d\u1ecbch c\u1ed5 phi\u1ebfu nh\u01b0 CPRX:<\/p>\n<ul>\n<li><strong>S\u1ed1 ti\u1ec1n n\u1ea1p t\u1ed1i thi\u1ec3u ch\u1ec9 5 USD<\/strong> &#8211; ho\u00e0n h\u1ea3o \u0111\u1ec3 th\u1eed nghi\u1ec7m chi\u1ebfn l\u01b0\u1ee3c v\u1edbi r\u1ee7i ro t\u1ed1i thi\u1ec3u<\/li>\n<li><strong>X\u00e1c minh nhanh ch\u00f3ng<\/strong> &#8211; b\u1eaft \u0111\u1ea7u giao d\u1ecbch nhanh v\u1edbi vi\u1ec7c t\u1ea3i l\u00ean t\u00e0i li\u1ec7u \u0111\u01a1n gi\u1ea3n<\/li>\n<li><strong>Nhi\u1ec1u l\u1ef1a ch\u1ecdn r\u00fat ti\u1ec1n<\/strong> &#8211; linh ho\u1ea1t trong vi\u1ec7c ti\u1ebfp c\u1eadn l\u1ee3i nhu\u1eadn c\u1ee7a b\u1ea1n<\/li>\n<li><strong>N\u1ec1n t\u1ea3ng th\u00e2n thi\u1ec7n v\u1edbi ng\u01b0\u1eddi d\u00f9ng<\/strong> &#8211; giao di\u1ec7n tr\u1ef1c quan l\u00fd t\u01b0\u1edfng cho vi\u1ec7c h\u1ecdc \u0111\u1ea7u t\u01b0 c\u00f4ng ngh\u1ec7 sinh h\u1ecdc<\/li>\n<\/ul>\n<h2>\ud83c\udf0d Catalyst Pharmaceuticals N\u0103m 2025: Chuy\u00ean Gia B\u1ec7nh Hi\u1ebfm<\/h2>\n<p>Catalyst Pharmaceuticals chi\u1ebfm l\u0129nh th\u1ecb tr\u01b0\u1eddng b\u1ec7nh th\u1ea7n kinh hi\u1ebfm v\u1edbi s\u1ea3n ph\u1ea9m ch\u1ee7 l\u1ef1c Firdapse, \u0111i\u1ec1u tr\u1ecb H\u1ed9i Ch\u1ee9ng Lambert-Eaton Myasthenic (LEMS). C\u00f4ng ty \u0111\u00e3 chuy\u1ec3n m\u00ecnh t\u1eeb l\u0129nh v\u1ef1c \u0111i\u1ec1u tr\u1ecb nghi\u1ec7n sang tr\u1edf th\u00e0nh <a href=\"https:\/\/catalystpharma.com\/about-catalyst\/\">chuy\u00ean gia b\u1ec7nh hi\u1ebfm t\u1eadp trung<\/a> v\u1edbi ph\u01b0\u01a1ng ph\u00e1p ti\u1ebfp c\u1eadn c\u00f3 s\u1ee9 m\u1ec7nh r\u00f5 r\u00e0ng.<\/p>\n<p>S\u1ef1 chuy\u1ec3n \u0111\u1ed5i t\u00e0i ch\u00ednh \u1ea5n t\u01b0\u1ee3ng c\u1ee7a c\u00f4ng ty \u0111\u01b0\u1ee3c ch\u1ee9ng minh qua v\u1ecb tr\u00ed <a href=\"https:\/\/dcfmodeling.com\/blogs\/history\/cprx-history-mission-ownership\">th\u1ee9 n\u0103m trong danh s\u00e1ch 50 c\u00f4ng ty Mid-Cap th\u00e0nh c\u00f4ng nh\u1ea5t n\u01b0\u1edbc M\u1ef9 n\u0103m 2025 c\u1ee7a Forbes<\/a> v\u1edbi doanh thu g\u1ea7n 500 tri\u1ec7u USD m\u1ed7i n\u0103m.<\/p>\n<p><strong>S\u1ef1 th\u1eadt th\u00fa v\u1ecb cho n\u0103m 2025:<\/strong> C\u00e1c ch\u01b0\u01a1ng tr\u00ecnh h\u1ed7 tr\u1ee3 b\u1ec7nh nh\u00e2n c\u1ee7a Catalyst hi\u1ec7n bao g\u1ed3m gi\u00e1m s\u00e1t tu\u00e2n th\u1ee7 \u0111i\u1ec1u tr\u1ecb b\u1eb1ng AI &#8211; s\u1eed d\u1ee5ng h\u1ecdc m\u00e1y \u0111\u1ec3 d\u1ef1 \u0111o\u00e1n b\u1ec7nh nh\u00e2n n\u00e0o c\u00f3 th\u1ec3 c\u1ea7n h\u1ed7 tr\u1ee3 th\u00eam d\u1ef1a tr\u00ean m\u1eabu \u0111\u01a1n thu\u1ed1c v\u00e0 d\u1eef li\u1ec7u k\u1ebft qu\u1ea3 l\u00e2m s\u00e0ng.<\/p>\n"},"faq":[{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 b\u1eaft \u0111\u1ea7u mua c\u1ed5 phi\u1ebfu CPRX?","answer":"B\u1ea1n c\u1ea7n ch\u1ecdn m\u1ed9t n\u1ec1n t\u1ea3ng giao d\u1ecbch c\u00f3 truy c\u1eadp NASDAQ, n\u1ea1p ti\u1ec1n v\u00e0o t\u00e0i kho\u1ea3n, t\u00ecm ki\u1ebfm m\u00e3 CPRX, ch\u1ecdn lo\u1ea1i l\u1ec7nh ph\u00f9 h\u1ee3p v\u00e0 x\u00e1c nh\u1eadn giao d\u1ecbch."},{"question":"Catalyst Pharmaceuticals t\u1eadp trung v\u00e0o l\u0129nh v\u1ef1c n\u00e0o?","answer":"Catalyst Pharmaceuticals chuy\u00ean v\u1ec1 \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh hi\u1ebfm, \u0111\u1eb7c bi\u1ec7t l\u00e0 H\u1ed9i Ch\u1ee9ng Lambert-Eaton Myasthenic (LEMS) v\u1edbi s\u1ea3n ph\u1ea9m ch\u1ee7 l\u1ef1c Firdapse."},{"question":"R\u1ee7i ro l\u1edbn nh\u1ea5t khi \u0111\u1ea7u t\u01b0 v\u00e0o CPRX l\u00e0 g\u00ec?","answer":"R\u1ee7i ro l\u1edbn nh\u1ea5t l\u00e0 c\u00e1c quy\u1ebft \u0111\u1ecbnh ti\u00eau c\u1ef1c t\u1eeb FDA c\u00f3 th\u1ec3 khi\u1ebfn c\u1ed5 phi\u1ebfu gi\u1ea3m m\u1ea1nh, c\u00f9ng v\u1edbi s\u1ef1 ph\u1ee5 thu\u1ed9c l\u1edbn v\u00e0o doanh thu t\u1eeb Firdapse."},{"question":"D\u1ef1 b\u00e1o gi\u00e1 c\u1ed5 phi\u1ebfu CPRX trong t\u01b0\u01a1ng lai nh\u01b0 th\u1ebf n\u00e0o?","answer":"D\u1ef1 b\u00e1o cho th\u1ea5y gi\u00e1 c\u1ed5 phi\u1ebfu c\u00f3 th\u1ec3 t\u0103ng l\u00ean 25-28 USD v\u00e0o cu\u1ed1i n\u0103m 2025 v\u00e0 ti\u1ebfp t\u1ee5c t\u0103ng \u0111\u1ebfn 29-34 USD trong n\u0103m 2026, v\u1edbi ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng d\u00e0i h\u1ea1n."},{"question":"Nh\u1eefng l\u1eddi khuy\u00ean n\u00e0o d\u00e0nh cho nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi khi mua CPRX?","answer":"Nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi n\u00ean \u00e1p d\u1ee5ng chi\u1ebfn l\u01b0\u1ee3c trung b\u00ecnh chi ph\u00ed \u0111\u00f4 la, \u0111\u1eb7t c\u1ea3nh b\u00e1o l\u1ee3i nhu\u1eadn, qu\u1ea3n l\u00fd r\u1ee7i ro b\u1eb1ng c\u00e1ch kh\u00f4ng \u0111\u1ea7u t\u01b0 qu\u00e1 5-10% danh m\u1ee5c v\u00e0o c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc v\u00e0 duy tr\u00ec quan \u0111i\u1ec3m \u0111\u1ea7u t\u01b0 d\u00e0i h\u1ea1n."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 b\u1eaft \u0111\u1ea7u mua c\u1ed5 phi\u1ebfu CPRX?","answer":"B\u1ea1n c\u1ea7n ch\u1ecdn m\u1ed9t n\u1ec1n t\u1ea3ng giao d\u1ecbch c\u00f3 truy c\u1eadp NASDAQ, n\u1ea1p ti\u1ec1n v\u00e0o t\u00e0i kho\u1ea3n, t\u00ecm ki\u1ebfm m\u00e3 CPRX, ch\u1ecdn lo\u1ea1i l\u1ec7nh ph\u00f9 h\u1ee3p v\u00e0 x\u00e1c nh\u1eadn giao d\u1ecbch."},{"question":"Catalyst Pharmaceuticals t\u1eadp trung v\u00e0o l\u0129nh v\u1ef1c n\u00e0o?","answer":"Catalyst Pharmaceuticals chuy\u00ean v\u1ec1 \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh hi\u1ebfm, \u0111\u1eb7c bi\u1ec7t l\u00e0 H\u1ed9i Ch\u1ee9ng Lambert-Eaton Myasthenic (LEMS) v\u1edbi s\u1ea3n ph\u1ea9m ch\u1ee7 l\u1ef1c Firdapse."},{"question":"R\u1ee7i ro l\u1edbn nh\u1ea5t khi \u0111\u1ea7u t\u01b0 v\u00e0o CPRX l\u00e0 g\u00ec?","answer":"R\u1ee7i ro l\u1edbn nh\u1ea5t l\u00e0 c\u00e1c quy\u1ebft \u0111\u1ecbnh ti\u00eau c\u1ef1c t\u1eeb FDA c\u00f3 th\u1ec3 khi\u1ebfn c\u1ed5 phi\u1ebfu gi\u1ea3m m\u1ea1nh, c\u00f9ng v\u1edbi s\u1ef1 ph\u1ee5 thu\u1ed9c l\u1edbn v\u00e0o doanh thu t\u1eeb Firdapse."},{"question":"D\u1ef1 b\u00e1o gi\u00e1 c\u1ed5 phi\u1ebfu CPRX trong t\u01b0\u01a1ng lai nh\u01b0 th\u1ebf n\u00e0o?","answer":"D\u1ef1 b\u00e1o cho th\u1ea5y gi\u00e1 c\u1ed5 phi\u1ebfu c\u00f3 th\u1ec3 t\u0103ng l\u00ean 25-28 USD v\u00e0o cu\u1ed1i n\u0103m 2025 v\u00e0 ti\u1ebfp t\u1ee5c t\u0103ng \u0111\u1ebfn 29-34 USD trong n\u0103m 2026, v\u1edbi ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng d\u00e0i h\u1ea1n."},{"question":"Nh\u1eefng l\u1eddi khuy\u00ean n\u00e0o d\u00e0nh cho nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi khi mua CPRX?","answer":"Nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi n\u00ean \u00e1p d\u1ee5ng chi\u1ebfn l\u01b0\u1ee3c trung b\u00ecnh chi ph\u00ed \u0111\u00f4 la, \u0111\u1eb7t c\u1ea3nh b\u00e1o l\u1ee3i nhu\u1eadn, qu\u1ea3n l\u00fd r\u1ee7i ro b\u1eb1ng c\u00e1ch kh\u00f4ng \u0111\u1ea7u t\u01b0 qu\u00e1 5-10% danh m\u1ee5c v\u00e0o c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc v\u00e0 duy tr\u00ec quan \u0111i\u1ec3m \u0111\u1ea7u t\u01b0 d\u00e0i h\u1ea1n."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>C\u00e1ch mua c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX)\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-24T13:49:09+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX)\",\"datePublished\":\"2025-08-24T13:49:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\"},\"wordCount\":23,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\",\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX)\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"datePublished\":\"2025-08-24T13:49:09+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/vt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vt-VT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX)","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-24T13:49:09+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX)","datePublished":"2025-08-24T13:49:09+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"},"wordCount":23,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"vt-VT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/","name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX)","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","datePublished":"2025-08-24T13:49:09+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#breadcrumb"},"inLanguage":"vt-VT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/vt\/"},{"@type":"ListItem","position":2,"name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX)"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/vt\/#website","url":"https:\/\/pocketoption.com\/blog\/vt\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vt-VT"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"vt_VT","wpml_translations":{"pt_AA":{"locale":"pt_AA","id":344699,"slug":"how-to-buy-catalyst-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da Catalyst Pharmaceuticals, Inc. (CPRX) - Investimento em a\u00e7\u00f5es da Catalyst Pharmaceuticals, Inc. (CPRX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/344702","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/comments?post=344702"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/344702\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media\/334072"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media?parent=344702"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/categories?post=344702"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/tags?post=344702"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}